OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
July 02, 2022
As we reach further afield in the molecular universe, we encounter new types of problems to resolve.
Systemic inefficiencies in the pharmaceutical industry undermine problem-solving efforts.
June 30, 2022
Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.
June 24, 2022
Novartis will endorse the Kigali Declaration on neglected tropical diseases and invest $250 million for R&D.
GSK will invest £1 billion in furthering R&D in malaria, tuberculosis, and HIV, as well as neglected tropical diseases.
June 21, 2022
Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites.
Orbit Discovery has been awarded the Innovate UK Grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery.
June 17, 2022
A new polymer surface material has been invented by researchers in Sweden that uses electrical signals to both capture and release biomolecules.